1ghq: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:
|PDB= 1ghq |SIZE=350|CAPTION= <scene name='initialview01'>1ghq</scene>, resolution 2.04&Aring;
|PDB= 1ghq |SIZE=350|CAPTION= <scene name='initialview01'>1ghq</scene>, resolution 2.04&Aring;
|SITE=  
|SITE=  
|LIGAND= <scene name='pdbligand=NDG:2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE'>NDG</scene> and <scene name='pdbligand=ZN:ZINC ION'>ZN</scene>
|LIGAND= <scene name='pdbligand=NDG:2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE'>NDG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>
|ACTIVITY=  
|ACTIVITY=  
|GENE=  
|GENE=  
|DOMAIN=
|RELATEDENTRY=
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ghq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ghq OCA], [http://www.ebi.ac.uk/pdbsum/1ghq PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1ghq RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
Complement receptor 2 (CR2/CD21) is an important receptor that amplifies B lymphocyte activation by bridging the innate and adaptive immune systems. CR2 ligands include complement C3d and Epstein-Barr virus glycoprotein 350/220. We describe the x-ray structure of this CR2 domain in complex with C3d at 2.0 angstroms. The structure reveals extensive main chain interactions between C3d and only one short consensus repeat (SCR) of CR2 and substantial SCR side-side packing. These results provide a detailed understanding of receptor-ligand interactions in this protein family and reveal potential target sites for molecular drug design.
Complement receptor 2 (CR2/CD21) is an important receptor that amplifies B lymphocyte activation by bridging the innate and adaptive immune systems. CR2 ligands include complement C3d and Epstein-Barr virus glycoprotein 350/220. We describe the x-ray structure of this CR2 domain in complex with C3d at 2.0 angstroms. The structure reveals extensive main chain interactions between C3d and only one short consensus repeat (SCR) of CR2 and substantial SCR side-side packing. These results provide a detailed understanding of receptor-ligand interactions in this protein family and reveal potential target sites for molecular drug design.
==Disease==
Known diseases associated with this structure: C3 deficiency OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120700 120700]], Macular degeneration, age-related, 9 OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120700 120700]], Systemic lupus erythematosus, susceptibility to, 9 OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120650 120650]]


==About this Structure==
==About this Structure==
Line 30: Line 30:
[[Category: Li, D.]]
[[Category: Li, D.]]
[[Category: Szakonyi, G.]]
[[Category: Szakonyi, G.]]
[[Category: NDG]]
[[Category: ZN]]
[[Category: c3d]]
[[Category: c3d]]
[[Category: cr2]]
[[Category: cr2]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 11:23:12 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 20:44:11 2008''